<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303497</url>
  </required_header>
  <id_info>
    <org_study_id>ANGIO-TAX-PLUS-0906</org_study_id>
    <nct_id>NCT01303497</nct_id>
  </id_info>
  <brief_title>Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas</brief_title>
  <acronym>ANGIO-TAX+</acronym>
  <official_title>Phase II Study, Multicenter, Randomized, Stratified, Evaluating the Efficacity of Weekly Paclitaxel, With or Without Bevacizumab in the Treatment of Metastatic or Locally Advanced Angiosarcomas Not Accessible to Surgery Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Sarcome Français</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe d’études des Tumeurs Osseuses</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomization is stratified :

        -  angiosarcoma in irradiated region : yes / no

        -  visceral angiosarcoma : yes / no

      All patient will received a maximum of 6 cycles of weekly Paclitaxel (Arm A and B) in
      association or not with Bevacizumab (ArmB).

      1 cycle = 28 days Treatment by Bevacizumab is to continue beyond the 6th cycle, until disease
      progression or unacceptable toxicity

      Arm A and B:

      Day 1, D8 and D15 Paclitaxel : 90 mg/m², IV weekly with premedication

      Arm B :

      Day 1 and D15 Bevacizumab : 10 mg/kg and then, Bevacizumab : 15 mg/kg/3 weeks until disease
      progression or unacceptable toxicity
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free rate after 6 months of treatment</measure>
    <time_frame>after 6 months of treatment</time_frame>
    <description>Stable disease, complete response and partial response according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response at 3, 6, 9 months of treatment</measure>
    <time_frame>at 3, 6, 9 months of treatment</time_frame>
    <description>Stable disease, complete response and partial response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free rate</measure>
    <time_frame>an average time period of 1 year</time_frame>
    <description>Median time for both cohort between :
date of inclusion
date of clinical or radiological progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global median survival</measure>
    <time_frame>an average time period of 18 months</time_frame>
    <description>Median time for both cohort between :
date of inclusion
date of death whatever the cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>during the study</time_frame>
    <description>According to NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between efficacity and serum expression of anti angiogenic factors</measure>
    <time_frame>Day 1, 8, 15, 29 and 57</time_frame>
    <description>Blood samples at different times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between efficacity and beta-tubuline III expression in tissue</measure>
    <time_frame>At baseline</time_frame>
    <description>Paraffin blocks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Angiosarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A : Paclitaxel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>administration of paclitaxel drug during cycle of 28 days (6 cycles Max) + blood sample on day 1, 8, 15, 29 and 57</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : Paclitaxel + Bevacizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>administration of paclitaxel drug during per cycle of 28 days (6 cycles Max) + Bevacizumab every two weeks during paclitaxel cycles then every 3 weeks during P cycles until disease progression or inacceptable toxicity
+ blood sample on day 1, 8, 15, 29 and 57</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)</description>
    <arm_group_label>Arm A : Paclitaxel</arm_group_label>
    <arm_group_label>Arm B : Paclitaxel + Bevacizumab</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab until progression or inacceptable toxicity :
During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV
After 6 cycles of chemotherapy : 15 mg/kg, IV</description>
    <arm_group_label>Arm B : Paclitaxel + Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Angiosarcoma histologically proven

          -  Metastatic or locally advanced and not accessible to surgery treatment

          -  Measurable tumor with at least 1 measurable lesion, according to RECIST

          -  For angiosarcoma in irradiated region, absence of clinical arguments of progression of
             the tumor prior treated by radiation

          -  At least 28 days since the previous treatment (systemic or major surgery)

          -  Performance Status (ECOG) ≤ 1

          -  Man or woman &gt;= 18 years

          -  Polynuclear neutrophils &gt;1500/mm3, platelets &gt; 100 000/ mm3, Hemoglobin &gt; 9.0 g/dl

          -  Total bilirubin ≤ 1.5 x USL, AST and ALT ≤ 2.5 x USL (or ≤ 5 if hepatic metastasis )

          -  Serum creatinin ≤ 1.5 x USL or clearance calculated &gt; 50 ml/mn (Cockcroft formulae)

          -  Absence of hematuria on dipstick

          -  Proteinuria on dipstick &lt;2+, if &gt;2, the 24 hours proteinuria must be &lt; 1g

          -  Albumin &gt; 35 g/l and lymphocytes &gt; 700/mm3 attesting a life expectancy &gt; 3 months

          -  Normal cardiac function : LVEF ≥ 50%

          -  Normal coagulation test : INR ≤ 1.5 and TCA ≤ 1.5 x USL within 7 days before inclusion

          -  Systolic BP ≤ 150 mmHg and diastolic BP ≤ 100 mmHg

          -  Negative pregnancy test for women of reproductive potential(within 7 days before
             treatment start)

          -  Effective contraceptive methods for male and female (if applicable) during the period
             of treatment and until the 6 months after the last administration of Bevacizumab

          -  Adequate central veinous access

          -  Patient covered by government health insurance

          -  Informed consent form signed by the patient

        Exclusion Criteria:

          -  Patients that have received more than 2 regimens of chemotherapy whatever the
             indication

          -  Kaposi's sarcoma, hemangio-endothelioma, hemangio-pericytoma (Malignant solitary
             fibrous tumor)

          -  Surgery (except the diagnostic biopsy) or radiotherapy within the past 4 weeks before
             inclusion, except antalgic radiotherapy

          -  Uncontrolled, active peptic ulcer,

          -  Other malignant evolutive tumor

          -  Previous thrombotic or hemorrhagic disorders

          -  Clinically significant cardiovascular disease (stroke within 6 months prior inclusion,
             unstable angina, heart failure, myocardial infarction, arrhythmia requiring treatment)

          -  Anticoagulant treatment for curative aim within 10 days before beginning of treatment
             (oral or parenteral administration), aspirin &gt; 325 mg/day, or Plavix or a thrombolytic
             (thrombolytics for preventive use is permitted) or anti-platelet (dipyridamol,
             ticlopidine, clodiprogel, cilostazol)

          -  Chronic treatment(more than 15 days) by every AINS including aspirin &gt; 325 mg/j

          -  Currently active bacterial or fungus infection (grade &gt; 2 CTCAE v4.02)

          -  Known HIV1, HIV2, hepatitis B or hepatitis C infections

          -  Presence of known meningeal or brain metastasis

          -  Epilepsy requiring the use of anti-epileptic

          -  Previous organ transplant

          -  Peripheral stem cell transplantation within 4 months prior to inclusion in the study

          -  Using of drugs affecting the biological response, for example G-CSF, within the 3
             weeks before inclusion

          -  Kidney dialysis patient

          -  Clinically significant neuropathy (grade&gt; 2 CTCAE V4.02)

          -  Any circumstance that could jeopardise compliance or proper follow-up during the trial

          -  Pregnant or nursing women. Women should not breastfeed for at least 6 months after the
             last administration of Bevacizumab

          -  Constitutional or acquired coagulopathy

          -  Uncontrolled hypertension (SBP&gt; 150 mmHg or DBP&gt; 100 mmHg)

          -  Known hypersensitivity to paclitaxel or to one of its excipients (Cremophor EL, to
             Bevacizumab components, to products of Chinese hamster ovary cells (CHO) or other
             recombinant human or humanized antibodies

          -  Patients unable to undergo trail medical follow-up for geographical, social or
             psychological reasons

          -  Patient refusal of ambulatory care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas PENEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>SAINT PRIEST en JAREZ</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiosarcoma</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

